Corebridge Financial Inc. Sells 2,665 Shares of Altimmune, Inc. (NASDAQ:ALT)

Corebridge Financial Inc. reduced its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 7.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 35,312 shares of the company’s stock after selling 2,665 shares during the period. Corebridge Financial Inc.’s holdings in Altimmune were worth $255,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the stock. SBI Securities Co. Ltd. purchased a new stake in shares of Altimmune in the fourth quarter valued at about $45,000. Cullen Frost Bankers Inc. bought a new stake in Altimmune in the fourth quarter worth about $72,000. 180 Wealth Advisors LLC purchased a new stake in shares of Altimmune during the 4th quarter worth approximately $78,000. KLP Kapitalforvaltning AS purchased a new position in Altimmune in the fourth quarter valued at approximately $81,000. Finally, Raymond James Financial Inc. purchased a new stake in Altimmune in the fourth quarter worth $88,000. Institutional investors own 78.05% of the company’s stock.

Insider Transactions at Altimmune

In other news, CFO Gregory L. Weaver bought 10,000 shares of Altimmune stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average price of $5.20 per share, with a total value of $52,000.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 4.10% of the stock is owned by insiders.

Altimmune Price Performance

ALT opened at $4.41 on Friday. Altimmune, Inc. has a one year low of $3.55 and a one year high of $11.16. The firm has a market capitalization of $339.63 million, a P/E ratio of -2.85 and a beta of 0.91. The company has a fifty day moving average price of $5.62 and a 200-day moving average price of $6.80.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. On average, analysts expect that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ALT has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Altimmune in a research report on Thursday, April 3rd. Stifel Nicolaus began coverage on Altimmune in a research report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target for the company. Finally, William Blair reiterated a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Altimmune currently has a consensus rating of “Moderate Buy” and an average target price of $20.83.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.